Bernadino Flashcards
IBD Epidemiology
- Equal men and women (jews>non)
- Bimodal distribution
- 1st peak is 15-25 y.o.
- 2nd peak is +60 y.o.
Symptoms of UC
bloody diarrhea and tenesmus
Symptoms of CD
nonbloody diarrhea, ab pain, weight loss, anorexia
Infectious mimics of IBD
Shigella, E. Coli, Campylobacter, Salmonella, C. diff, Vibrio, CMV
UC
inflammatory disease affecting mucosa of rectum and parts of colon (continous)
- chronic and relapsing
- neutrophilic crypt abscess
pANCA (+)
CD
pan-enteric transmural inflammatory disease (mouth to sigmoid --> spares rectum) - skip lesions (usually terminal ileum) - granulomas!!! - painful diarrhea, anemia ASCA (+)
IBD Extraintestinal manifestations
Musculoskeletal –> arthritis, ankylosing spondylitis, osteoporosis, sacroilitis
Skin and Mouth –> erythema nodosum, apthous ulcers, vitiligo, psoriasis, amyloidosis, pyoderma gangrenosum
Ocular –> uveitis, iritis, episcleritis
Hepatobiliary –> primary sclerosing cholangitis, cholangiocarcinoma, hepatitis
Complications of UC
toxic megacolon, hemorrhage, stricture, CRC
Complications of CD
abscess, perforation, obstruction, hemorrhage, CRCV
CRC in IBD
increased risk at 10 and 30 years
- increased risk with proximal disease, long duration, fmaily history
5-ASA is protective
Pathogenesis of IBD
abnormal function of gut mucosal barrier –> chronic inflammation
- there is genetic suceptibility
- dysregulation of mucosal inflammatory immunity (Th1)
- decreased Treg cells
Environmental Influences
“Clean Kid hypothesis”
- more common in cold climates, industrialized areas,
Expectations of IBD treatment
- induce clinical remission
- maintain remission
- improve quality of life
Induction therapy
5-ASA Steroids Infliximab Cyclosporine Surgery
Maintenance therapy
5-ASA
Immunomodulators
Infliximab
Causes of Lower GI bleeding
Upper GI - 10%
Small Bowel - 5%
Colon - 85%